NASDAQ:CVAC CureVac (CVAC) Stock Price, News & Analysis $2.74 -0.11 (-3.86%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$2.70▼$2.8950-Day Range$2.74▼$3.7952-Week Range$2.21▼$8.93Volume500,913 shsAverage Volume956,949 shsMarket Capitalization$613.43 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get CureVac alerts: Email Address CureVac MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside265.0% Upside$10.00 Price TargetShort InterestHealthy6.06% of Float Sold ShortDividend StrengthN/ASustainability-1.86Upright™ Environmental ScoreNews Sentiment0.99Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthDecreasingFrom $0.05 to ($0.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.57 out of 5 starsMedical Sector242nd out of 910 stocksPharmaceutical Preparations Industry105th out of 426 stocks 3.1 Analyst's Opinion Consensus RatingCureVac has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.Amount of Analyst CoverageCureVac has only been the subject of 1 research reports in the past 90 days.Read more about CureVac's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted6.06% of the float of CureVac has been sold short.Short Interest Ratio / Days to CoverCureVac has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in CureVac has recently decreased by 10.03%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldCureVac does not currently pay a dividend.Dividend GrowthCureVac does not have a long track record of dividend growth. Previous Next 4.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCureVac has received a 80.46% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "mRNA vaccines" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for CureVac is -1.86. Previous Next 3.3 News and Social Media Coverage News SentimentCureVac has a news sentiment score of 0.99. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CureVac this week, compared to 2 articles on an average week.Search Interest3 people have searched for CVAC on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, CureVac insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.15% of the stock of CureVac is held by insiders.Percentage Held by InstitutionsOnly 17.26% of the stock of CureVac is held by institutions.Read more about CureVac's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for CureVac are expected to decrease in the coming year, from $0.05 to ($0.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of CureVac is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CureVac is -2.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Growth RatioCureVac has a PEG Ratio of 2.23. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioCureVac has a P/B Ratio of 1.51. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about CureVac's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Sasco Gold LLCSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." I believe the American people deserve to control the fate of their own life savings which is why I had my team put together our latest guide to protect your hard-earned wealth before it's too late... [RUSH MY FREE GUIDE] About CureVac Stock (NASDAQ:CVAC)CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza. The company also develops CV8102, which is in Phase 1 clinical trial for treating melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck; and CVGBM for treating cancer. CureVac N.V. was founded in 2000 and is headquartered in Tübingen, Germany.Read More CVAC Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CVAC Stock News HeadlinesSeptember 2, 2024 | markets.businessinsider.comCureVac (CVAC) Receives a Hold from Deutsche BankAugust 23, 2024 | sg.finance.yahoo.comGinkgo Bioworks Holdings, Inc. (DNA.MX)September 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 21, 2024 | finance.yahoo.comNews Flash: 8 Analysts Think CureVac N.V. (NASDAQ:CVAC) Earnings Are Under ThreatAugust 20, 2024 | uk.finance.yahoo.comCUREVAC (1CVAC.MI)August 20, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: CureVac (CVAC), Vericel (VCEL) and Twist Bioscience (TWST)August 16, 2024 | markets.businessinsider.comCureVac: A Promising Buy Amidst Financial Stability and Innovative Vaccine PipelineAugust 15, 2024 | markets.businessinsider.comEQS-News: CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected GlioblastomaSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… August 15, 2024 | markets.businessinsider.comEQS-News: CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business UpdateAugust 15, 2024 | finance.yahoo.comCureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected GlioblastomaAugust 1, 2024 | finance.yahoo.comWe Think CureVac (NASDAQ:CVAC) Can Afford To Drive Business GrowthJuly 22, 2024 | finance.yahoo.comCVAC Aug 2024 2.000 put (CVAC240816P00002000)July 11, 2024 | businesswire.comAgomab Bolsters Executive Team with Appointment of Pierre Kemula as Chief Financial OfficerJuly 4, 2024 | seekingalpha.comCureVac: GSK's Deal For Infectious Disease Assets Is A Long-Shot For Both PharmasJuly 3, 2024 | investorplace.comCureVac Layoffs 2024: What to Know About the Latest CVAC Job CutsJuly 3, 2024 | barrons.comGSK Will Pay Up to $1.5 Billion for CureVac's mRNA VaccinesJuly 3, 2024 | investorplace.comCVAC Stock Alert: CureVac Pops on Licensing Deal With GSKSee More Headlines Receive CVAC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CureVac and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/29/2020Today9/07/2024Next Earnings (Estimated)11/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CVAC CUSIPN/A CIK1809122 Webwww.curevac.com Phone49-70-71988-30Fax49-7071-9883Employees1,172Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$16.00 Low Stock Price Target$4.00 Potential Upside/Downside+265.0%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.33) Trailing P/E RatioN/A Forward P/E Ratio54.80 P/E Growth2.23Net Income$-281,580,000.00 Net Margins-422.66% Pretax Margin-419.62% Return on Equity-57.18% Return on Assets-38.60% Debt Debt-to-Equity Ratio0.09 Current Ratio2.29 Quick Ratio2.28 Sales & Book Value Annual Sales$65.86 million Price / Sales9.31 Cash FlowN/A Price / Cash FlowN/A Book Value$1.81 per share Price / Book1.51Miscellaneous Outstanding Shares223,880,000Free Float219,067,000Market Cap$613.43 million OptionableOptionable Beta2.62 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesDr. Alexander Zehnder M.B.A. (Age 54)M.D., CEO, MD & Member of Management Board Comp: $1.05MMr. Pierre Kemula B.Sc. (Age 49)MD, CFO & Member of Management Board Comp: $700.97kDr. Malte Greune Ph.D. (Age 59)COO, Member of Management Board & MD Comp: $643.71kDr. Myriam Mendila M.D. (Age 58)Chief Development Officer, MD & Member of the Management Board Comp: $658.44kDr. Ulrike Gnad-Vogt M.D. (Age 51)Ph.D., Senior VP & Area Head of Oncology Comp: $304.47kDr. Sarah FakihVice President Corporate Communications & Investor RelationsMr. Marco Rau L.L.M.Ph.D., General CounselMr. Thorsten SchullerHead of Corporate CommunicationsSlavica Stevanovic-HeckHead of Human ResourcesDr. Patrick BaumhofSenior Vice President of TechnologyMore ExecutivesKey CompetitorsACADIA PharmaceuticalsNASDAQ:ACADAmneal PharmaceuticalsNASDAQ:AMRXGeronNASDAQ:GERNPTC TherapeuticsNASDAQ:PTCTAgios PharmaceuticalsNASDAQ:AGIOView All CompetitorsInstitutional OwnershipPoint72 Asset Management L.P.Bought 2,422,728 shares on 8/19/2024Ownership: 1.082%Vanguard Personalized Indexing Management LLCBought 21,999 shares on 8/12/2024Ownership: 0.020%XTX Topco LtdBought 31,646 shares on 8/12/2024Ownership: 0.014%Signaturefd LLCBought 15,403 shares on 7/30/2024Ownership: 0.010%Bank of New York Mellon CorpBought 15,804 shares on 7/26/2024Ownership: 0.007%View All Institutional Transactions CVAC Stock Analysis - Frequently Asked Questions How have CVAC shares performed this year? CureVac's stock was trading at $4.21 at the beginning of 2024. Since then, CVAC shares have decreased by 34.9% and is now trading at $2.74. View the best growth stocks for 2024 here. How were CureVac's earnings last quarter? CureVac (NASDAQ:CVAC) announced its earnings results on Sunday, November, 29th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($54.37) by $54.13. CureVac had a negative trailing twelve-month return on equity of 57.18% and a negative net margin of 422.66%. When did CureVac IPO? CureVac (CVAC) raised $200 million in an initial public offering (IPO) on Friday, August 14th 2020. The company issued 13,300,000 shares at $14.00-$16.00 per share. BofA Securities, Jefferies and Credit Suisse acted as the underwriters for the IPO and Berenberg and Kempen were co-managers. Who are CureVac's major shareholders? Top institutional investors of CureVac include Point72 Asset Management L.P. (1.08%), Vanguard Personalized Indexing Management LLC (0.02%), XTX Topco Ltd (0.01%) and Signaturefd LLC (0.01%). How do I buy shares of CureVac? Shares of CVAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of CureVac own? Based on aggregate information from My MarketBeat watchlists, some other companies that CureVac investors own include Moderna (MRNA), Tesla (TSLA), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Pfizer (PFE) and This page (NASDAQ:CVAC) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CureVac Please log in to your account or sign up in order to add this asset to your watchlist. Share CureVac With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CVAC Stock Alerts